SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-062939
Filing Date
2023-11-13
Accepted
2023-11-13 16:10:09
Documents
14
Period of Report
2023-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K igms-20231113.htm   iXBRL 8-K 47289
2 EX-99.1 igms-ex99_1.htm EX-99.1 205986
3 GRAPHIC img140404641_0.jpg GRAPHIC 3792
  Complete submission text file 0000950170-23-062939.txt   390826

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT igms-20231113_pre.xml EX-101.PRE 10275
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT igms-20231113_lab.xml EX-101.LAB 14018
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT igms-20231113.xsd EX-101.SCH 2451
8 EXTRACTED XBRL INSTANCE DOCUMENT igms-20231113_htm.xml XML 4937
Mailing Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043
Business Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043 650-965-7873
IGM Biosciences, Inc. (Filer) CIK: 0001496323 (see all company filings)

IRS No.: 770349194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39045 | Film No.: 231398753
SIC: 2834 Pharmaceutical Preparations